Feedback / Questions
coltuximab ravtansine (SAR3419) - ImmunoGen
Q1 '11 results
(Sanofi)
-
Apr 28, 2011 -
Company's maytansin-loaded anti-CD19 mAb SAR3419 is currently in early stage pipeline of P1 study
http://www.larvolonline.com/tlg/ccdb/SanofiAventisQ111ResultsApr28.pdf
Apr 28, 2011
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious